TipRanks
Bicycle Therapeutics Ltd (DE:50BA)
FRANKFURT:50BA
Germany Market
50BA
Bicycle Therapeutics
RESEARCH TOOLSreports

Bicycle Therapeutics (50BA) Stock Forecast & Price Target

1 Followers
See the Price Targets and Ratings of:

50BA Analyst Ratings

Moderate Buy
6Ratings
Moderate Buy
3 Buy
3 Hold
0 Sell
Based on 6 analysts giving stock ratings to
Bicycle
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

50BA Stock 12 Month Forecast

Average Price Target

€7.98
▲(130.73% Upside)
Based on 6 Wall Street analysts offering 12 month price targets for Bicycle Therapeutics in the last 3 months. The average price target is €7.98 with a high forecast of €12.08 and a low forecast of €4.32. The average price target represents a 130.73% change from the last price of €3.46.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"€2","13":"€13","4.75":"€4.75","7.5":"€7.5","10.25":"€10.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":12.08284,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€12.08</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7.983305,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€7.98</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4.3153,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€4.32</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,4.75,7.5,10.25,13],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.46,4.123295384615385,4.786590769230769,5.449886153846154,6.1131815384615384,6.776476923076923,7.439772307692308,8.103067692307693,8.766363076923078,9.429658461538462,10.092953846153847,10.756249230769232,11.419544615384616,{"y":12.08284,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.46,3.8079465384615383,4.155893076923077,4.503839615384615,4.851786153846154,5.199732692307692,5.547679230769231,5.895625769230769,6.2435723076923075,6.591518846153846,6.939465384615384,7.287411923076923,7.635358461538462,{"y":7.983305,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.46,3.5257923076923077,3.5915846153846154,3.657376923076923,3.723169230769231,3.7889615384615385,3.854753846153846,3.9205461538461535,3.9863384615384616,4.052130769230769,4.117923076923077,4.183715384615384,4.249507692307692,{"y":4.3153,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":6.2,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.35,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.8,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.2,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.5,"date":1767225600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":5.2,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.64,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.92,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.92,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.92,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.62,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.34,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.46,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€12.08Average Price Target€7.98Lowest Price Target€4.32
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Morgan Stanley Analyst forecast on DE:50BA
Maxwell Skor
Morgan Stanley
Morgan Stanley
€10.36→
Hold
―
Reiterated
08/17/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: OmniAb (NASDAQ: OABI), Bicycle Therapeutics (NASDAQ: BCYC) and 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP)
Truist Financial Analyst forecast on DE:50BA
Gregory Renza
Truist Financial
Truist Financial
€6.04
Hold
74.61%
Upside
Reiterated
07/31/26
Truist Financial Remains a Hold on Bicycle Therapeutics (BCYC)
Oppenheimer Analyst forecast on DE:50BA
Jeff Jones
Oppenheimer
Oppenheimer
€31.07→€9.49
Buy
174.38%
Upside
Initiated
07/31/26
Bicycle Therapeutics assumed with an Outperform at OppenheimerBicycle Therapeutics assumed with an Outperform at Oppenheimer
Needham Analyst forecast on DE:50BA
Ami Fadia
Needham
Needham
€12.95→€12.08
Buy
249.22%
Upside
Reiterated
07/30/26
Analysts Offer Insights on Healthcare Companies: Bicycle Therapeutics (NASDAQ: BCYC), Alnylam Pharma (NASDAQ: ALNY) and Fortrea Holdings Inc. (NASDAQ: FTRE)
RBC Capital Analyst forecast on DE:50BA
Leonid Timashev
RBC Capital
RBC Capital
€4.32
Hold
24.72%
Upside
Reiterated
07/30/26
RBC Capital Keeps Their Hold Rating on Bicycle Therapeutics (BCYC)
TD Cowen Analyst forecast on DE:50BA
Tara Bancroft
TD Cowen
TD Cowen
―
Buy
―
Reiterated
07/30/26
Analysts Conflicted on These Healthcare Names: Alnylam Pharma (NASDAQ: ALNY), Stryker (NYSE: SYK) and Bicycle Therapeutics (NASDAQ: BCYC)
Jefferies Analyst forecast on DE:50BA
Maury Raycroft
Jefferies
Jefferies
€11.22→€10.36
Buy
199.33%
Upside
Reiterated
04/30/26
Bicycle Therapeutics price target lowered to $12 from $13 at JefferiesBicycle Therapeutics price target lowered to $12 from $13 at Jefferies
Citizens JMP Analyst forecast on DE:50BA
Reni Benjamin
Citizens JMP
Citizens JMP
€10.36→€6.9
Buy
99.55%
Upside
Reiterated
03/18/26
Bicycle Therapeutics price target lowered to $8 from $12 at CitizensBicycle Therapeutics price target lowered to $8 from $12 at Citizens
H.C. Wainwright Analyst forecast on DE:50BA
Swayampakula Ramakanth
H.C. Wainwright
H.C. Wainwright
€28.48
Buy
723.15%
Upside
Reiterated
10/31/25
Buy Rating for Bicycle Therapeutics: Strong Upside Potential Amid Clinical and Financial Developments
Barclays Analyst forecast on DE:50BA
Peter Lawson
Barclays
Barclays
€12.95
Buy
274.16%
Upside
Reiterated
10/31/25
Barclays Sticks to Its Buy Rating for Bicycle Therapeutics (BCYC)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Morgan Stanley Analyst forecast on DE:50BA
Maxwell Skor
Morgan Stanley
Morgan Stanley
€10.36→
Hold
―
Reiterated
08/17/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: OmniAb (NASDAQ: OABI), Bicycle Therapeutics (NASDAQ: BCYC) and 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP)
Truist Financial Analyst forecast on DE:50BA
Gregory Renza
Truist Financial
Truist Financial
€6.04
Hold
74.61%
Upside
Reiterated
07/31/26
Truist Financial Remains a Hold on Bicycle Therapeutics (BCYC)
Oppenheimer Analyst forecast on DE:50BA
Jeff Jones
Oppenheimer
Oppenheimer
€31.07→€9.49
Buy
174.38%
Upside
Initiated
07/31/26
Bicycle Therapeutics assumed with an Outperform at OppenheimerBicycle Therapeutics assumed with an Outperform at Oppenheimer
Needham Analyst forecast on DE:50BA
Ami Fadia
Needham
Needham
€12.95→€12.08
Buy
249.22%
Upside
Reiterated
07/30/26
Analysts Offer Insights on Healthcare Companies: Bicycle Therapeutics (NASDAQ: BCYC), Alnylam Pharma (NASDAQ: ALNY) and Fortrea Holdings Inc. (NASDAQ: FTRE)
RBC Capital Analyst forecast on DE:50BA
Leonid Timashev
RBC Capital
RBC Capital
€4.32
Hold
24.72%
Upside
Reiterated
07/30/26
RBC Capital Keeps Their Hold Rating on Bicycle Therapeutics (BCYC)
TD Cowen Analyst forecast on DE:50BA
Tara Bancroft
TD Cowen
TD Cowen
―
Buy
―
Reiterated
07/30/26
Analysts Conflicted on These Healthcare Names: Alnylam Pharma (NASDAQ: ALNY), Stryker (NYSE: SYK) and Bicycle Therapeutics (NASDAQ: BCYC)
Jefferies Analyst forecast on DE:50BA
Maury Raycroft
Jefferies
Jefferies
€11.22→€10.36
Buy
199.33%
Upside
Reiterated
04/30/26
Bicycle Therapeutics price target lowered to $12 from $13 at JefferiesBicycle Therapeutics price target lowered to $12 from $13 at Jefferies
Citizens JMP Analyst forecast on DE:50BA
Reni Benjamin
Citizens JMP
Citizens JMP
€10.36→€6.9
Buy
99.55%
Upside
Reiterated
03/18/26
Bicycle Therapeutics price target lowered to $8 from $12 at CitizensBicycle Therapeutics price target lowered to $8 from $12 at Citizens
H.C. Wainwright Analyst forecast on DE:50BA
Swayampakula Ramakanth
H.C. Wainwright
H.C. Wainwright
€28.48
Buy
723.15%
Upside
Reiterated
10/31/25
Buy Rating for Bicycle Therapeutics: Strong Upside Potential Amid Clinical and Financial Developments
Barclays Analyst forecast on DE:50BA
Peter Lawson
Barclays
Barclays
€12.95
Buy
274.16%
Upside
Reiterated
10/31/25
Barclays Sticks to Its Buy Rating for Bicycle Therapeutics (BCYC)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
AXGNAxoGen
ASNDAscendis Pharma
HROWHarrow Health
IRTCIrhythm Technologies
DNLIDenali Therapeutics
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Bicycle Therapeutics

3 Months
Reni BenjaminCitizens JMP
Success Rate
13/34 ratings generated profit
38%
Average Return
-5.05%
Copying Reni Benjamin's trades and holding each position for 3 Months would result in 38.24% of your transactions generating a profit, with an average return of -5.05% per trade.
1 Year
Reni BenjaminCitizens JMP
Success Rate
8/34 ratings generated profit
24%
Average Return
-26.96%
Copying Reni Benjamin's trades and holding each position for 1 Year would result in 23.53% of your transactions generating a profit, with an average return of -26.96% per trade.
2 Years
Peter LawsonBarclays
Success Rate
1/16 ratings generated profit
6%
Average Return
-62.72%
Copying Peter Lawson's trades and holding each position for 2 Years would result in 6.25% of your transactions generating a profit, with an average return of -62.72% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

50BA Analyst Recommendation Trends

Rating
May 26
Jun 26
Jul 26
Aug 26
Sep 26
Strong Buy
8
5
4
2
2
Buy
2
1
1
1
1
Hold
6
4
4
3
3
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
16
10
9
6
6
In the current month, 50BA has received 3 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. 50BA average Analyst price target in the past 3 months is 7.98.
Each month's total comprises the sum of three months' worth of ratings.

50BA Financial Forecast

50BA Earnings Forecast

Next quarter’s earnings estimate for 50BA is -€0.34 with a range of -€0.56 to -€0.03. The previous quarter’s EPS was -€0.62. 50BA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 50BA has Performed in-line its overall industry.
Next quarter’s earnings estimate for 50BA is -€0.34 with a range of -€0.56 to -€0.03. The previous quarter’s EPS was -€0.62. 50BA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 50BA has Performed in-line its overall industry.

50BA Sales Forecast

Next quarter’s sales forecast for 50BA is €10.46M with a range of €543.74K to €29.22M. The previous quarter’s sales results were €539.58K. 50BA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 50BA has Performed in-line its overall industry.
Next quarter’s sales forecast for 50BA is €10.46M with a range of €543.74K to €29.22M. The previous quarter’s sales results were €539.58K. 50BA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 50BA has Performed in-line its overall industry.

50BA Stock Forecast FAQ

What is DE:50BA’s average 12-month price target, according to analysts?
Based on analyst ratings, Bicycle Therapeutics Ltd’s 12-month average price target is 7.98.
    What is DE:50BA’s upside potential, based on the analysts’ average price target?
    Bicycle Therapeutics Ltd has 130.73% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Bicycle Therapeutics Ltd a Buy, Sell or Hold?
          Bicycle Therapeutics Ltd has a consensus rating of Moderate Buy, which is based on 3 buy ratings, 3 hold ratings and 0 sell ratings.
            What is Bicycle Therapeutics Ltd’s share price target?
            The average share price target for Bicycle Therapeutics Ltd is 7.98. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €12.08 ,and the lowest forecast is €4.32. The average share price target represents 130.73% Increase from the current price of €3.46.
              What do analysts say about Bicycle Therapeutics Ltd?
              Bicycle Therapeutics Ltd’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 6 Wall Streets Analysts.
                How can I buy shares of Bicycle Therapeutics Ltd?
                To buy shares of DE:50BA, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.